BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jul 27, 2015
 |  BioCentury  |  Finance

From pore to rich

How Oxford Nanopore regained the U.K.'s top private money raised spot

Oxford Nanopore Technologies Ltd. has chosen investors that look more like a public company's - and now the nanopore-based sequencing company has a valuation to match.

Oxford Nanopore raised £70 million ($109.2 million) last week with new and existing investors in the U.K., U.S. and continental Europe. The financing brings the company's total money raised to £251 million ($391.6 million), making Oxford one of only two U.K. biotechs to have raised more than $200 million as private companies.

The other isImmunocore Ltd., which raised a record-breaking $320 million in a series A round this month, for a total of $332.7 million raised.

The only...

Read the full 522 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >